R
Richard E. Champlin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1500
Citations - 73470
Richard E. Champlin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 138, co-authored 1402 publications receiving 66917 citations.
Papers
More filters
Journal ArticleDOI
Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation with Sorafenib
Manish Sharma,Farhad Ravandi,Ulas D. Bayraktar,Alexandre Chiattone,Qaiser Bashir,Sergio Giralt,Julianne Chen,Muzaffar H. Qazilbash,Partow Kebriaei,Marina Konopleva,Michael Andreeff,Jorge E. Cortes,Deborah McCue,Hagop M. Kantarjian,Richard E. Champlin,Marcos de Lima +15 more
TL;DR: Sorafenib is not effective in the treatment of FLT3-ITD-positive AML relapsing after HSCT, and preventive strategies afterHSCT may be more suitable for these high-risk patients.
Journal ArticleDOI
Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: Comparison with bone marrow transplantation
Ronald Paquette,Neyssan Tebyani,Margaret Frane,Priscilla Ireland,Winston G. Ho,Richard E. Champlin,Stephen D. Nimer +6 more
TL;DR: The results suggest a superior long-term outcome for adult patients with SAA treated with BMT rather than with ATG alone, using current protocols.
Journal ArticleDOI
Molecular epidemiology of cytomegalovirus infections associated with bone marrow transplantation
Drew J. Winston,Eng-Shang Huang,Marjorie J. Miller,Cheng-Hsein Lin,Winston G. Ho,Robert Peter Gale,Richard E. Champlin +6 more
TL;DR: The results suggest that some cytomegalovirus infections after bone marrow transplantation may be caused by strains present before transplantation.
Journal ArticleDOI
Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life
Gheath Alatrash,Marcos de Lima,Nelson Hamerschlak,Matteo Pelosini,Xuemei Wang,Lianchun Xiao,Fabio R. Kerbauy,Alexandre Chiattone,Gabriela Rondon,Muzaffar H. Qazilbash,Sergio Giralt,Leandro de Padua Silva,Chitra Hosing,Partow Kebriaei,Weiqing Zhang,Yago Nieto,Rima M. Saliba,Richard E. Champlin,Borje S. Andersson +18 more
TL;DR: The results suggest that age alone should not be the primary reason for exclusion from receiving myeloablative reduced-toxicity conditioning with i.v. Bu-Flu preceding transplantation in patients with AML/MDS.
Journal ArticleDOI
Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation. Preliminary results of a controlled trial.
Drew J. Winston,Winston G. Ho,Cheng Hsien Lin,Miriam D. Budinger,Richard E. Champlin,Robert Peter Gale +5 more
TL;DR: Preliminary results suggest that intravenous immunoglobulin can modify the severity of cytomegalovirus infection and prevent interstitial pneumonia in bone marrow transplant recipients.